GLP1R and digestive system disorder: Importantly, all RCTs reported that treatment with GLP-1 RAs was well tolerated with a rate of adverse events not exceeding that of either placebo or reference therapy, except for a greater frequency of transient, mild-to-moderate gastrointestinal disorders.